5.60
+0.19
(3.51%)
May 17 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 5.40 - 5.65 |
| 52 week | 1.75 - 5.65 |
| Open | 5.45 |
| Vol / Avg. | 126,347.00/27,169.00 |
| Mkt cap | 782.92M |
| P/E | - |
| Div/yield | - |
| EPS | -1.08 |
| Shares | 139.81M |
| Beta | 1.22 |
| Inst. own | - |
Events
Jun 12, 2013
Q2 2013 Patheon Inc Earnings Release
Mar 28, 2013
Patheon Inc Annual and Special Shareholder Meeting
Mar 8, 2013
Q1 2013 Patheon Inc Earnings Conference Call
Mar 4, 2013
Q1 2013 Patheon Inc Earnings Release
|
|
Key stats and ratios
| Q1 (Jan '13) | 2012 | |
| Net profit margin | -24.07% | -14.20% |
| Operating margin | -5.76% | -4.93% |
| EBITD margin | - | 9.54% |
| Return on average assets | -22.96% | -13.58% |
| Return on average equity | -171.88% | -58.78% |
| Employees | 4,700 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 4721 Emperor Blvd
DURHAM, NC 27703-8580
United States - Map
+1-919-2263200 (Phone)
+1-919-4742269 (Fax)
DURHAM, NC 27703-8580
United States - Map
+1-919-2263200 (Phone)
+1-919-4742269 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Patheon Inc. is a provider of commercial manufacturing outsourcing services (CMO) and outsourced pharmaceutical development services (PDS) to the global pharmaceutical industry. The Company operates in two segments: CMO and PDS. The Company�s PDS business provides a range of development services, including finished dosage formulation across approximately 40 dosage forms, early development services, analytical services, formulation expertise and life cycle management. The Company�s PDS segments operate eight development centers located throughout North America and Europe. The Company�s CMO business focuses primarily on prescription products in a range of solid and sterile dosage forms. The Company�s CMO segments operate nine facilities located throughout North America and Europe.In September 2012, Patheon sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions.
Officers and directors
| Paul S. Levy | Chairman of the Board | |
| James C. Mullen | Chief Executive Officer, Director | |
| Stuart R. Grant | Chief Financial Officer, Executive Vice President | |
| Geoffrey M. Glass | President - Product and Technology Commercialization | |
| Michael J. Lehmann | President - Global Pharmaceutical Development Services | |
| Antonella Mancuso | President - Global Commercial Operations, Chief Manufacturing Officer | |
| Paul M. Garofolo | Executive Vice President - PDS Global Business Operations, Chief Technology Officer | |
| Aqueel A. Fatmi Ph.D. | Executive Vice President - Global Research & Development, Chief Scientific Officer | |
| Michael E. Lytton | Executive Vice President - Corporate Development and Strategy, General Counsel | |
| Rebecca Holland New | Senior Vice President - Human Resources |